NeurAxis (NRXS) Competitors $2.61 +0.05 (+1.95%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$2.61 0.00 (0.00%) As of 07:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRXS vs. HYPR, BDMD, APYX, VANI, ICCM, NTRB, LUNG, QTI, TELA, and CTSOShould you be buying NeurAxis stock or one of its competitors? The main competitors of NeurAxis include Hyperfine (HYPR), Baird Medical Investment (BDMD), Apyx Medical (APYX), Vivani Medical (VANI), IceCure Medical (ICCM), Nutriband (NTRB), Pulmonx (LUNG), QT Imaging (QTI), TELA Bio (TELA), and Cytosorbents (CTSO). These companies are all part of the "medical equipment" industry. NeurAxis vs. Its Competitors Hyperfine Baird Medical Investment Apyx Medical Vivani Medical IceCure Medical Nutriband Pulmonx QT Imaging TELA Bio Cytosorbents Hyperfine (NASDAQ:HYPR) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings. Does the media favor HYPR or NRXS? In the previous week, NeurAxis had 2 more articles in the media than Hyperfine. MarketBeat recorded 2 mentions for NeurAxis and 0 mentions for Hyperfine. Hyperfine's average media sentiment score of 0.00 beat NeurAxis' score of -0.50 indicating that Hyperfine is being referred to more favorably in the media. Company Overall Sentiment Hyperfine Neutral NeurAxis Negative Which has more volatility and risk, HYPR or NRXS? Hyperfine has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, NeurAxis has a beta of 3.1, indicating that its stock price is 210% more volatile than the S&P 500. Do institutionals and insiders hold more shares of HYPR or NRXS? 15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 31.0% of Hyperfine shares are owned by insiders. Comparatively, 26.4% of NeurAxis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings and valuation, HYPR or NRXS? NeurAxis has lower revenue, but higher earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHyperfine$12.89M8.47-$40.72M-$0.52-2.67NeurAxis$3.22M8.01-$14.63M-$0.99-2.64 Is HYPR or NRXS more profitable? Hyperfine has a net margin of -364.54% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Hyperfine's return on equity.Company Net Margins Return on Equity Return on Assets Hyperfine-364.54% -84.82% -69.39% NeurAxis -492.76%N/A -641.25% Do analysts prefer HYPR or NRXS? Hyperfine presently has a consensus target price of $1.28, suggesting a potential downside of 7.67%. NeurAxis has a consensus target price of $7.00, suggesting a potential upside of 168.20%. Given NeurAxis' stronger consensus rating and higher probable upside, analysts plainly believe NeurAxis is more favorable than Hyperfine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hyperfine 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67NeurAxis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryHyperfine beats NeurAxis on 9 of the 16 factors compared between the two stocks. Get NeurAxis News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXS vs. The Competition Export to ExcelMetricNeurAxisElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.27M$39.96M$5.78B$10.26BDividend YieldN/AN/A5.74%4.64%P/E Ratio-1.423.7176.7426.98Price / Sales8.01184.49512.93165.01Price / CashN/A41.3637.1760.63Price / Book-9.672.5613.536.37Net Income-$14.63M-$2.66M$3.29B$271.46M7 Day Performance7.63%2.95%1.57%2.53%1 Month Performance10.59%15.35%6.82%9.42%1 Year Performance-15.66%208.02%77.92%30.16% NeurAxis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXSNeurAxis2.2037 of 5 stars$2.61+2.0%$7.00+168.2%-10.6%$25.27M$3.22M-1.4219News CoverageHYPRHyperfine1.0483 of 5 stars$1.27+6.7%$1.28+1.0%+44.8%$93.51M$12.89M-2.44190BDMDBaird Medical InvestmentN/A$2.44-1.2%N/AN/A$88.25MN/A0.00N/AGap DownAPYXApyx Medical2.6045 of 5 stars$2.06flatN/A+113.3%$77.91M$48.10M-4.58270Short Interest ↓Gap UpVANIVivani Medical3.5028 of 5 stars$1.28flat$4.00+212.5%+20.5%$75.83MN/A-2.8420Insider TradeGap UpICCMIceCure Medical2.4333 of 5 stars$1.03-1.9%$2.39+131.6%+60.8%$72.13M$3.29M-6.4460News CoverageNTRBNutriband2.8005 of 5 stars$6.08-2.9%$13.00+113.8%+42.9%$69.82M$2.14M-6.7610News CoverageAnalyst DowngradeShort Interest ↓LUNGPulmonx3.0824 of 5 stars$1.69-0.6%$7.66+353.5%-81.0%$69.27M$83.79M-1.18250QTIQT ImagingN/A$2.52+1.6%N/A+317.2%$68.38M$4.00M0.00N/ATELATELA Bio2.5293 of 5 stars$1.60-1.2%$4.50+181.3%-40.9%$64.18M$69.30M-1.43120CTSOCytosorbents2.4473 of 5 stars$1.00+1.6%$5.50+451.1%-34.3%$61.66M$35.60M-5.87220Analyst Forecast Related Companies and Tools Related Companies Hyperfine Alternatives Baird Medical Investment Alternatives Apyx Medical Alternatives Vivani Medical Alternatives IceCure Medical Alternatives Nutriband Alternatives Pulmonx Alternatives QT Imaging Alternatives TELA Bio Alternatives Cytosorbents Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRXS) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeurAxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeurAxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NRXS Stock Alerts